AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00972556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diluted (20%) Formocresol (DFC)
Description: After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
Study NCT02991729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad-based decision aid
Description: This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
Study NCT02991729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling appointment
Description: All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
Study NCT02991729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic counseling appointment
Description: All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
Study NCT02337452 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02337452 — intervention group
Intervention type: BEHAVIORAL
Intervention: Web Site
Description: Communicate via family outreach program website
Study NCT03432793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: oral tablet, QD
Study NCT04318730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.
Study NCT01238224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: This is an acute study. Tadalafil 20 mg administered prior to a meal
Study NCT01238224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: This is an acute study. Tadalafil 20 mg administered prior to a meal
Study NCT00332683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintaining low (15mmHg) ETT cuff pressure
Description: Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
Study NCT00332683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintaining a normal pressure in the ETT cuff
Description: No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
Study NCT00154310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
Study NCT00154310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Tablets orally twice a day to maintain protocol specific target blood levels
Study NCT00154310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium
Description: Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
Study NCT00154310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium
Description: Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
Study NCT00154310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
Study NCT00154310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
Study NCT02991443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
Study NCT03148977 — intervention group
Intervention type: PROCEDURE
Intervention: Graft
Description: Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
Study NCT01291238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthier, Smarter, Happier
Description: Increased physical activity and decreased sugar and fat intake during school hours
Study NCT00101660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets; oral; 70 mg BID, depending on response
Study NCT04138342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quantum dots coated with veldoreotide
Description: The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
Study NCT04138342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical approved placebo
Description: The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
Study NCT02086552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02086552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02086552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Given PO
Study NCT01948180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: baltaleucel-T
Description: Autologous EBV-specific T-cells
Study NCT03427190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: APSOM vs Control
Description: In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
Study NCT03427190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APSOM vs Control
Description: In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
Study NCT03495804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol
Description: Experimental group was given polyethylene glycol as oral contrast agent.
Study NCT03495804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: Active comparator group was given mannitol as oral contrast agent.
Study NCT00326638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy
Description: IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~* Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~* Boost IMRT to Prostate 3,200 cGy/16
Study NCT00326638 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm A: 3D-Conformal Radiation
Description: 3DCRT 7800 cGY/39 Fractions/ STD Technique\* once daily Monday to Friday for 8 weeks~* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~* Boost 6 F 3DCRT to Prostate 3,200 cGy/16
Study NCT02321280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Single dose subcutaneous administration
Study NCT03101241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-8998
Description: T-type calcium channel blocker
Study NCT03101241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04203537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery
Study NCT04203537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local administration during surgery
Study NCT03592277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
Study NCT03592277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
Study NCT02186080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Study NCT02186080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01543412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
Study NCT03511417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: over-the-counter hearing device
Description: Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
Study NCT03432793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: oral tablet, QD
Study NCT03432793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral tablet solution, QD
Study NCT03432793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: oral solution, single dose
Study NCT01908322 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
Study NCT01781390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for infusion.
Study NCT01781390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPC) 12.5 M
Description: MPC 12.5 M solution for infusion.
Study NCT01781390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPC) 25 M
Description: MPC 25 M solution for infusion.
Study NCT01351532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation program
Description: cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
Study NCT01351532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
Study NCT03996941 — intervention group
Intervention type: BEHAVIORAL
Intervention: Harm reduction of informal PrEP use
Description: Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit.
Study NCT03996941 — intervention group
Intervention type: OTHER
Intervention: PrEP follow up based on point of care testing
Description: The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
Study NCT05973318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzotimol eye drops, 20 mg/mL + 5 mg/mL
Description: Dosing schedule b.i.d.
Study NCT05973318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt eye drops, 20 mg/mL + 5 mg/mL
Description: Dosing schedule b.i.d.
Study NCT02235363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thread lift
Description: In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
Study NCT03169634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: short or long stemmed rTKR cemented
Description: An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
Study NCT03169634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone with short stem
Description: Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
Study NCT03169634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone with long stem
Description: Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
Study NCT04325087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: Administration of an iTBS protocol over the dlPFC
Study NCT04325087 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iTBS
Description: Administration of a placebo TMS protocol over the dlPFC
Study NCT00612157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone 3mg orally at bedtime for 14 nights
Study NCT00612157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matching placebo
Study NCT00192023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine 0.5 mg/kg/day
Description: atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
Study NCT00192023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atomoxetine 0.5 mg/kg/day
Description: atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
Study NCT00192023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00192023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine 1.2 mg/kg/day
Description: atomoxetine 1.2 mg/kg/day QD, PO
Study NCT00192023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine 1.2-1.4 mg/kg/day
Description: atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
Study NCT00192023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atomoxetine 1.2-1.4 mg/kg/day
Description: atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
Study NCT01108757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bactrim
Description: Bactrim DS BID for 3 days
Study NCT01108757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn starch capsules
Study NCT04194996 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical intervention
Description: Surgical interventions will be patient specified by treating surgeon.
Study NCT02390427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Study NCT00225225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone
Study NCT00225225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Study NCT00225225 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: dietary recommendation for weight maintenance
Study NCT02390427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Study NCT02390427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Study NCT02390427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02390427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04241744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin 125 MG po BID
Description: prevention to develop CDI during hospitalization
Study NCT04241744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin 125 MG po BID
Description: prevention to develop CDI during hospitalization
Study NCT02419430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBRT ClassRoom and Phone Application
Description: 2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
Study NCT02419430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone application only
Description: Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~* Joys of Life~* Count your blessings~* Think differenc, feel better~* Exercising --> Happier~  + Exercising --> Sleep~* Pre-Sleep routine~* Eat that frog~* Mindful Meditation
Study NCT02419430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Simvastatin FDC
Description: Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg tablet
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Matching placebo to sitagliptin 100 mg tablet
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to sitagliptin
Description: Matching placebo to sitagliptin 100 mg tablet
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to simvastatin
Description: Matching placebo to simvastatin 40 mg tablet
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to simvastatin
Description: Matching placebo to simvastatin 40 mg tablet
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Sitagliptin/Simvastatin FDC
Description: Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
Study NCT01516502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-level laser therapy
Description: An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
Study NCT01516502 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: low-level laser therapy
Description: An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
Study NCT00024102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 \& 8 and 5-FU 600 mg/sq m IV push d 1 \& 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles